MT1980 · program
MT1980 for Schizophrenia
MT1980, Monument Therapeutics' brain-penetrant lipid reformulation of a marketed fibrate (a PPAR-alpha agonist), for schizophrenia in patients with elevated inflammation and persistent negative symptoms. Human data so far come from one completed single-dose Phase 1 in 24 healthy volunteers (NCT05429840, 2022; Groningen, Netherlands). It was well tolerated and drug reached the cerebrospinal fluid at every dose level (70, 140, 250 mg). At ECNP 2026 Monument presented the schizophrenia rationale and described next steps: a multiple-ascending-dose study in healthy volunteers, then a proof-of-principle study in schizophrenia patients selected for raised inflammatory markers and negative symptoms, with inflammatory and pharmacodynamic biomarkers. Neither study is registered. The multiple-dose Phase 1 has been described as planned since January 2023. The compound's indication focus has shifted over time, from post-operative cognitive decline (2021) to Alzheimer's disease, POCD and Long COVID (2023-2024) to inflammation-associated schizophrenia (2026).
Development timeline
- Conference presentationMT1980 presented for inflammation-associated schizophrenia at ECNP 2026 (poster PS01-1249)↗
- metFirst-in-human single-dose Phase 1 of MT1980 met all objectives: drug was found in the cerebrospinal fluid of every healthy volunteer, and there were no significant MT1980-related side effects.↗
- NCT05429840 completed (actual primary completion 2022-10-04, 24 participants). Monument reported on 2023-01-09 that the study met all objectives. A multiple-dose Phase 1 has been planned since then but is not registered.
- Trial (portion) completedMT1980 first-in-human Phase 1 completes (NCT05429840)
- First-in-human single-dose Phase 1 NCT05429840 (protocol PCD101) started per ClinicalTrials.gov. It enrolled healthy volunteers and was registered under 'Neuroinflammatory Response', not schizophrenia. Monument announced the start on 2022-06-13.
- Trial startedFirst-in-human Phase 1 of MT1980 starts (NCT05429840)
Readouts
- 2023-01-09ReportedTopline datametNCT05429840
First-in-human single-dose Phase 1 of MT1980 met all objectives: drug was found in the cerebrospinal fluid of every healthy volunteer, and there were no significant MT1980-related side effects. ↗
Clinical trials in Schizophrenia
NCT05429840PCD101Phase 1Completedn=24
A Two-part, Single Dose, Randomized, Single Blinded, Placebo Controlled, Phase I Study to Assess the Safety and Pharmacokinetics of Oral MT1980 in Healthy Volunteers When Dosed in the Fasted State
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| MT1980 oral lipid (LipiCore) formulationLipiCore lipid-based oral delivery (TRx Biosciences) Single oral doses of 70 mg, 140 mg or 250 mg versus placebo, given fasted, in the first-in-human Phase 1 study (NCT05429840). No repeat-dose regimen has been tested; a multiple-dose Phase 1 is planned. | Oral | Single dose | — |
Mechanism of action
MT1980 delivers a marketed fibrate-class lipid-modifying drug in a lipid formulation designed to raise systemic exposure and reach the brain. According to Monument's ECNP 2026 poster it acts as a PPAR-alpha agonist with additional anti-inflammatory actions. In preclinical studies, MT1980 and the standard formulation both lowered peripheral inflammatory markers, but only MT1980 significantly reduced inflammatory cytokines in brain tissue in a lipopolysaccharide (LPS) neuroinflammation model. The hypothesis is that central PPAR-alpha-mediated dampening of neuroinflammation, and the downstream effects on the kynurenine pathway, may improve negative symptoms in the subgroup of schizophrenia patients with raised inflammatory markers, while the drug's lipid-lowering effects address cardiometabolic burden.
| Target | Action | Affinity |
|---|---|---|
| PPAR-alphaprimaryPPARA | Agonist | —ⓘ |
← Full MT1980 compound page (identity, identifiers, all indications)
Sources
- Granger KT, Moran P, Caswell S, Barnett J. MT1980: translating anti-inflammatory and metabolic mechanisms into new treatment opportunities for schizophrenia. ECNP 2026, poster PS01-1249 — CNS Pulse (ECNP 2026 abstract)
- Monument Therapeutics announces first clinical study of MT1980 has successfully met all objectives (2023-01-09) — Monument Therapeutics
- Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980 (2024-09-17) — Monument Therapeutics
- Monument Therapeutics to present positive data for first clinical study of MT1980 at AD/PD conference (2023-03-28) — Monument Therapeutics
- Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference (2022-03-14) — Monument Therapeutics (via One Nucleus)
- NCT05429840 (PCD101) - Safety & PK of Single Doses of MT1980 — ClinicalTrials.gov (U.S. National Library of Medicine)
- Stratified medicine company Monument Therapeutics raises additional GBP 0.5 million to take anti-neuroinflammation candidate MT1980 into clinic (2021-12-14) — Monument Therapeutics